ArriVent BioPharma (AVBP) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed ArriVent BioPharma (AVBP) over the past year, losing 8.0% versus a loss of 14.6%. ArriVent BioPharma is the larger company by market cap ($821.5 million vs $590.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | ZVRA |
|---|---|---|
| Share price | $16.66 | $9.94 |
| Market cap | $821.47M | $590.27M |
| 1-day change | -0.77% | -3.21% |
| YTD return | -17.20% | +10.94% |
| 1-year return | -14.61% | -8.01% |
| 5-year return | — | -1.49% |
| P/E ratio (TTM) | — | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-3.62 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | $-166.31M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | — | -59.12% |
| Net margin | — | 78.17% |
| 52-week high | $35.83 | $15.04 |
| 52-week low | $11.36 | $8.01 |
| Distance from 52-week high | -53.50% | -33.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.41% | +151.51% |
| Average volume | 1.00M | 1.07M |
| Shares outstanding | 49.31M | 59.38M |
| Employees | 77 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Healthcare · Biotechnology · 77 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
AVBP vs ZVRA FAQ
Which is bigger, ArriVent BioPharma or Zevra Therapeutics?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $821.47M compared with $590.27M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, AVBP or ZVRA?
ZVRA returned -8.01% over the past 12 months, compared with -14.61% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.